Kaolinite composite diagnostic and therapeutic agent and preparation method and use thereof

Patent metadata

Field	Value
Publication number	US-11833205-B2
Application number	US-202218055388-A
Country	US
Kind code	B2
Filing date	Nov 14, 2022
Priority date	Nov 17, 2021
Publication date	Dec 5, 2023
Grant date	Dec 5, 2023

Abstract

The kaolinite composite diagnostic and therapeutic agent uses modified kaolinite as a carrier and is loaded with carbon nitride quantum dots and doxorubicin. The present disclosure provides a preparation method of the kaolinite composite diagnostic and therapeutic agent, including the following steps: S1: preparing the modified kaolinite by subjecting the pharmaceutical grade kaolinite to intercalation, exfoliation, and immersion wet etching; S2: subjecting the modified kaolinite and a carbon nitride quantum dot solution to ultrasonication, drying, and grinding to obtain a kaolinite composite containing the carbon nitride quantum dots; and S3: dissolving the doxorubicin in the dark, adding dissolved doxorubicin into the kaolinite composite containing the carbon nitride quantum dots, shaking in the dark for a period of time, and washing and drying to obtain the diagnostic and therapeutic agent containing the carbon nitride quantum dots and the doxorubicin.

First claim

What is claimed is:

1. A kaolinite composite diagnostic and therapeutic agent, wherein the kaolinite composite diagnostic and therapeutic agent comprises a carrier, wherein the carrier comprises modified kaolinite and the carrier is loaded with carbon nitride quantum dots and doxorubicin;
wherein the modified kaolinite is obtained by subjecting pharmaceutical grade kaolinite to intercalation, exfoliation, and immersion wet etching and the modified kaolinite comprises mesopores; and the carbon nitride quantum dots are supported on a surface and inside the mesopores of the modified kaolinite, and the doxorubicin is adsorbed on the surface and between layers of the modified kaolinite.

2. The kaolinite composite diagnostic and therapeutic agent according to claim 1 , wherein the carbon nitride quantum dots are supported on the surface and inside the mesopores of the modified kaolinite in a form of nanoparticles, and the doxorubicin is adsorbed on the surface and between the layers of the modified kaolinite through electrostatic bonding.

3. A preparation method of the kaolinite composite diagnostic and therapeutic agent according to claim 1 , comprising the following steps:
S1: preparing the modified kaolinite by subjecting the pharmaceutical grade kaolinite to intercalation, exfoliation, and immersion wet etching;
S2: subjecting the modified kaolinite and a carbon nitride quantum dot solution to ultrasonication, drying, and grinding to obtain a kaolinite composite containing the carbon nitride quantum dots;
S3: dissolving the doxorubicin in the dark, adding dissolved doxorubicin into the kaolinite composite containing the carbon nitride quantum dots, shaking in the dark for a period of time, and washing and drying to obtain the composite diagnostic and therapeutic agent containing the carbon nitride quantum dots and the doxorubicin.

4. The preparation method according to claim 3 , wherein in step S1, the pharmaceutical grade kaolinite is modified by stepwise intercalation with dimethyl sulfoxide and urea.

5. The preparation method according to claim 3 , wherein in step S2, the carbon nitride quantum dots are graphite-phase carbon nitride quantum dots; and the carbon nitride quantum dot solution is prepared by the following steps: (1) conducting calcination on melamine for 2 h to 6 h to obtain a light yellow carbon nitride powder; (2) dispersing the carbon nitride powder in water at a mass-volume ratio of 1 mg:1 mL, conducting ultrasonication in an intelligent microwave catalytic synthesis extractor for 12 h to 24 h, and allowing to stand; alternatively, dispersing the carbon nitride powder in a mixture of deionized water and hydrogen peroxide, conducting ultrasonic dispersion, transferring to the reaction kettle and heating at a constant temperature for a period of time; and (3) removing large particles by centrifugation to obtain a colorless and transparent supernatant, namely the carbon nitride quantum dot solution.

6. The preparation method according to claim 5 , wherein in step S2, the modified kaolinite and the carbon nitride quantum dot solution have a mass-volume ratio of (25-200) mg:20 mL.

7. The preparation method according to claim 3 , wherein in step S3, the doxorubicin is placed in a PBS, dissolved by shaking in the dark, and washed with absolute ethanol; and the doxorubicin has a mass not less than that of the kaolinite composite containing the carbon nitride quantum dots.

8. Use of the kaolinite composite diagnostic and therapeutic agent according to claim 1 , comprising applying the kaolinite composite diagnostic and therapeutic agent to implement tumor imaging and tumor cell inhibition.

Assignees

• Univ China Geosciences Wuhan

Inventors

• Yang Huaming
• Liao Juan

Classifications

• A61K47/02 Primary

  Inorganic compounds · CPC title

• A61K31/275

  Nitriles; Isonitriles · CPC title

• A61K31/704 Primary

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

• A61K41/0057 Primary

  Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent · CPC title

• A61K47/52

  the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient · CPC title